We further found that neuroblastoma cells that were pre-treated with a CNR2 antagonist (SR144528) were protected against GW405833 (p = 0.014, Student’s t-test), while pre-treatment with a CNR1 antagonist (otenabant) had no protective effect (Supplementary Fig. 4C, D). Here, CNR1 is linked to neuroblastoma.